9.2 Picornaviruses and coronaviruses

Picornavirus and Coronavirus Structure

Picornaviruses and coronaviruses are two families of positive-sense, single-stranded RNA viruses responsible for diseases ranging from the common cold to global pandemics. Despite sharing the same genome polarity, they differ dramatically in size, structure, and replication strategy. These differences shape how each virus spreads, causes disease, and responds to treatment.

Structural Characteristics

Picornaviruses are small (pico = small, rna = RNA), non-enveloped viruses.

• 22–30 nm in diameter with a genome of roughly 7.2–8.4 kb
• The capsid has icosahedral symmetry built from four structural proteins (VP1–VP4)
  • VP1, VP2, and VP3 form the outer surface and determine antigenicity
  • VP4 sits on the interior, directly contacting the RNA genome
• Because they lack an envelope, picornaviruses are resistant to detergents and can survive well in the environment (relevant for fecal-oral transmission of enteroviruses)

Coronaviruses are much larger and carry an envelope.

• 80–120 nm in diameter with a genome of approximately 26–32 kb, the largest of any RNA virus
• The envelope contains three key proteins:
  • Spike (S) protein projects outward, creating the crown-like ("corona") appearance on electron microscopy. It mediates receptor binding and membrane fusion.
  • Membrane (M) protein is the most abundant envelope protein and shapes the viral particle
  • Envelope (E) protein plays a role in viral assembly and release
• Inside, a helical nucleocapsid (N protein bound to RNA) packages the genome

Replication Mechanisms

Both families replicate in the cytoplasm, but their strategies differ.

Picornavirus replication:

1. The virus binds a specific host receptor (e.g., ICAM-1 for rhinoviruses, CD155 for poliovirus) and releases its RNA into the cytoplasm.
2. The RNA is translated as a single large polyprotein, which is then cleaved by viral proteases (2A and 3C) into individual functional proteins.
3. Translation initiation is cap-independent, relying on an internal ribosome entry site (IRES) in the 5' UTR. This is significant because the virus shuts down host cap-dependent translation to hijack the cell's ribosomes.
4. The replication cycle is fast (6–8 hours), ending in cell lysis and release of new virions.

Coronavirus replication:

1. The S protein binds a host receptor (e.g., ACE2 for SARS-CoV-2) and the envelope fuses with the host membrane.
2. The large genome is translated to produce a replicase polyprotein, which is processed into the RNA-dependent RNA polymerase (RdRp) and associated proteins.
3. A distinctive feature: the replicase generates a nested set of subgenomic mRNAs, each encoding one or a few proteins. This allows regulated expression of structural and accessory proteins.
4. Replication complexes associate with double-membrane vesicles (DMVs) derived from the ER, which shield viral RNA from host immune sensors.
5. New virions assemble at the ER-Golgi intermediate compartment (ERGIC) and exit via exocytosis.

Pathogenesis and Infection Outcomes

Picornaviruses typically cause lytic infections. The rapid replication cycle destroys host cells directly. Many picornaviruses enter through the gastrointestinal or respiratory tract, replicate locally, and may then spread systemically through viremia. Neurotropic strains like poliovirus can invade the central nervous system by traveling along nerve fibers or crossing the blood-brain barrier.

Coronaviruses can cause both lytic and persistent infections. Respiratory tract epithelial cells are the primary target, but some strains (notably SARS-CoV-2) infect cells in multiple organ systems because ACE2 is widely expressed. Severe disease often results not just from viral damage but from an excessive host inflammatory response, sometimes called a cytokine storm, where overproduction of pro-inflammatory cytokines (IL-6, TNF-α) causes tissue damage, particularly in the lungs.

Picornavirus Infections: Clinical Manifestations and Epidemiology

Poliovirus Infection

Poliovirus is the most historically significant picornavirus. It spreads by the fecal-oral route and replicates initially in the oropharynx and intestinal mucosa.

• Approximately 72% of infections are asymptomatic
• About 24% cause a minor illness (fever, sore throat, malaise) that resolves on its own
• Less than 1% develop paralytic poliomyelitis, where the virus destroys motor neurons in the anterior horn of the spinal cord, causing acute flaccid paralysis

The Global Polio Eradication Initiative has reduced wild poliovirus cases by over 99% since 1988. Wild poliovirus type 1 remains endemic only in Afghanistan and Pakistan. However, vaccine-derived poliovirus (VDPV) outbreaks still occur in regions with low oral polio vaccine (OPV) coverage, because the live-attenuated virus in OPV can revert to a neurovirulent form and circulate in under-immunized populations.

Rhinovirus and Enterovirus Infections

Rhinoviruses are the leading cause of the common cold, responsible for roughly 50% of upper respiratory infections. They produce nasal congestion, sore throat, and cough. Over 160 serotypes exist, which is why you can catch colds repeatedly. Rhinoviruses peak in spring and fall in temperate climates, partly because they replicate best at the cooler temperatures found in the nasal passages (~33°C).

Enteroviruses (including coxsackieviruses and echoviruses) cause a broader range of disease:

• Hand, foot, and mouth disease (usually coxsackievirus A16 or enterovirus A71) is common in young children, presenting with oral ulcers and vesicular rash on hands and feet
• Viral myocarditis, particularly from coxsackievirus B, involves inflammation of the heart muscle and can lead to dilated cardiomyopathy
• Aseptic meningitis presents with fever, headache, and neck stiffness but typically has a better prognosis than bacterial meningitis
• Herpangina (coxsackievirus A) causes painful ulcers on the soft palate and posterior pharynx
• Pleurodynia (Bornholm disease, coxsackievirus B) produces sharp, episodic chest or abdominal pain

Enteroviruses are most active in summer and early fall. They're stable in water and spread via the fecal-oral route, which is why outbreaks correlate with crowding and poor sanitation.

Epidemiological Factors and Surveillance

Several factors shape picornavirus epidemiology:

• Population density drives transmission, with higher rates in urban settings and institutional environments (daycares, schools)
• Hygiene practices directly reduce spread; hand washing is one of the most effective interventions
• Environmental stability matters: enteroviruses survive well in water and sewage, making environmental surveillance (testing wastewater) a valuable tool for detecting poliovirus circulation

Children and immunocompromised individuals carry the highest burden of disease. Developing immune systems are more susceptible, and immunosuppression can lead to prolonged viral shedding and chronic infections.

Molecular epidemiology tools like genomic sequencing and phylogenetic analysis allow public health teams to identify specific strains, track transmission chains, and detect emerging variants. These techniques directly inform vaccination campaigns and outbreak response.

Coronavirus Infections: Global Impact

SARS and MERS Outbreaks

Severe Acute Respiratory Syndrome (SARS) emerged in Guangdong, China in late 2002.

• The 2002–2003 outbreak caused over 8,000 cases and 774 deaths (case fatality rate ~10%)
• SARS-CoV originated in bats, with palm civets serving as intermediate hosts in live animal markets
• The outbreak was contained through aggressive public health measures (quarantine, contact tracing) and no cases have been reported since 2004

Middle East Respiratory Syndrome (MERS) was first identified in Saudi Arabia in 2012.

• It has a strikingly high case fatality rate of approximately 35%, but limited sustained human-to-human transmission has prevented large-scale pandemics
• Dromedary camels are the primary reservoir; most human cases trace back to camel exposure or healthcare settings
• Sporadic outbreaks continue, primarily on the Arabian Peninsula

Both SARS and MERS demonstrated that animal coronaviruses can jump to humans with devastating consequences, a pattern that repeated with SARS-CoV-2.

COVID-19 Pandemic

SARS-CoV-2, the virus causing COVID-19, triggered the most significant pandemic in a century.

• Over 500 million confirmed cases and more than 6 million deaths were reported by 2022, though true numbers are likely much higher
• The pandemic drove unprecedented disruptions to healthcare systems, economies, and daily life
• Vaccines were developed in record time: mRNA vaccines (Pfizer-BioNTech, Moderna), viral vector vaccines (AstraZeneca, J&J), and protein subunit vaccines (Novavax) all received emergency authorization within roughly a year of the virus being sequenced

The pandemic also exposed gaps in zoonotic disease surveillance and spurred investment in global monitoring networks and rapid diagnostic technologies, including lateral flow rapid antigen tests and next-generation sequencing for variant tracking.

Economic consequences were severe: global GDP contracted by 3.1% in 2020, the airline industry lost over $370$ billion, and supply chain disruptions affected industries worldwide.

Research and Social Impact

COVID-19 accelerated virology and vaccine research in ways that will shape the field for decades:

• mRNA vaccine technology moved from experimental to mainstream, with applications now being explored for influenza, RSV, and cancer
• Novel diagnostic approaches advanced, including RT-LAMP (isothermal amplification for faster field testing) and CRISPR-based diagnostics (e.g., SHERLOCK, DETECTR)

Socially, the pandemic shifted public health norms: mask-wearing became widespread, remote and hybrid work models became standard in many industries, and public awareness of infectious disease prevention increased substantially.

Picornavirus and Coronavirus Management

Diagnostic Approaches

• RT-PCR remains the gold standard for detecting viral RNA, offering high sensitivity and specificity. It can also be quantitative, helping assess viral load.
• Rapid antigen tests detect viral proteins and provide results in 15–30 minutes, making them useful for point-of-care and home testing. They're less sensitive than PCR, especially in early or low-viral-load infections.
• Serological tests measure antibody responses:
  • IgM antibodies appear early and suggest recent or active infection
  • IgG antibodies develop later and indicate past infection or vaccination
• Multiplex PCR panels can detect multiple respiratory pathogens (influenza, RSV, coronaviruses, rhinoviruses) from a single sample, which is valuable during respiratory virus season when symptoms overlap

Treatment Strategies

Picornavirus infections are primarily managed with supportive care: hydration, antipyretics, and rest. There are very few effective antivirals. Pleconaril, which blocks viral uncoating by binding the hydrophobic pocket in VP1, has shown some activity against enteroviruses but is not widely approved.

Coronavirus infections have more treatment options, particularly for COVID-19:

• Remdesivir is a nucleoside analog that inhibits the viral RNA-dependent RNA polymerase (RdRp), reducing viral replication
• Nirmatrelvir/ritonavir (Paxlovid) inhibits the SARS-CoV-2 main protease ($M^{pro}$), blocking polyprotein processing. Ritonavir is included as a pharmacokinetic booster.
• Dexamethasone, a corticosteroid, reduces mortality in severe COVID-19 by dampening the excessive inflammatory response. It's used only in patients requiring supplemental oxygen, not in mild cases.
• Monoclonal antibodies targeting the S protein provided passive immunity for high-risk patients, though their effectiveness decreased as new variants with S protein mutations emerged

Prevention and Control Measures

Vaccination is the cornerstone of prevention for both families:

• Poliovirus vaccines come in two forms: the inactivated polio vaccine (IPV), which is injected and cannot revert, and the oral polio vaccine (OPV), which is live-attenuated, cheaper, and easier to administer but carries a small risk of vaccine-derived outbreaks. Most high-income countries now use IPV exclusively.
• COVID-19 vaccines span multiple platforms (mRNA, viral vector, protein subunit, inactivated whole virus), and booster doses have been developed to address waning immunity and emerging variants.

Non-pharmaceutical interventions remain critical, especially early in outbreaks before vaccines are available:

• Hand hygiene reduces transmission of both picornaviruses (fecal-oral, contact) and coronaviruses (respiratory droplets, fomites)
• Respiratory etiquette and physical distancing limit airborne and droplet spread
• Environmental controls (ventilation, surface disinfection) reduce exposure

Surveillance systems that integrate clinical, laboratory, and epidemiological data are essential for early outbreak detection and guiding public health responses. Wastewater surveillance has proven especially useful for tracking both poliovirus and SARS-CoV-2 circulation in communities.

Research into broad-spectrum antivirals and pan-coronavirus vaccines targeting conserved epitopes continues, with the goal of improving preparedness for future outbreaks before they become pandemics.